Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Authors:
- 17 October 2016
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 18 (11) , 115
Abstract
Composite angiotensin receptor-neprilysin inhibition (ARNi) represents a novel pharmacologic strategy for treatment of heart failure with reduced ejection fraction (HFrEF). In the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial of 8399 subjects with HFrEF, treatment with the ARNi LCZ696 (sacubitril/valsartan) was associated with statistically important reductions in cardiovascular death, all-cause mortality, and the composite of cardiovascular death or heart failure hospitalization in comparison with enalapril. These data have supported the US and European regulatory approval of sacubitril/valsartan and guideline-based recommendations for its use in the treatment of selected patients with HFrEF. In this review, we discuss the evidence supporting use of ARNi in preference to angiotensin-converting enzyme-inhibitors or angiotensin receptor blockers in patients with HFrEF and identify a strategy for selection of appropriate patients for transition to ARNi in clinical practice.Keywords
This publication has 30 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- The Global Health and Economic Burden of Hospitalizations for Heart FailureJACC, 2014
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- Heart Failure–Associated Hospitalizations in the United StatesJACC, 2013
- Rehospitalization for Heart FailureJACC, 2013
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart FailureCirculation, 2002
- Racial Differences in the Outcome of Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991